Tenofovir disoproxil fumarate (tenofovir DF) is a type of anti-HIV medicine called a nucleoside reverse transcriptase inhibitor (NRTI). The prescription medicine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children 2 years of age and older. Tenofovir DF is always used in combination with other anti-HIV medicines.
Tenofovir DF is also a hepatitis B virus (HBV) reverse transcriptase inhibitor, approved by the FDA for the treatment of chronic HBV infection in adults. HBV is an opportunistic infection. An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems.
The Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the U.S. Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC), includes recommendations on the use of tenofovir DF to treat HBV infection in people who are also receiving combination antiretroviral therapy (ART) for HIV infection.
Before taking tenofovir DF, tell your health care provider:
Ask your health care provider about possible side effects from tenofovir DF. Your health care provider will tell you what to do if you have side effects.
Take tenofovir DF according to your health care provider’s instructions. Your health care provider will tell you how much tenofovir DF to take and when to take it. Before you start tenofovir DF and each time you get a refill, read any printed information that comes with your medicine.
More information about tenofovir DF is available: